The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Open accessAbstract
Activation of the tyrosine kinase of the c-src gene product, pp60c-src, has been shown to occur in nearly every primary colorectal carcinoma, and is found as early as in polyps of high malignant potential. However, no studies have addressed potential pp60c-src changes which occur during progression. To examine this question, we have studied kinase activity and protein levels in 7 colonic polyps, 19 primary lesions, and 19 liver metastases relative to normal colonic mucosa. Significant increases in tyrosine kinase activity were seen as early as in colonic polyps of high malignant potential. Further increases were observed in activity and level in primary tumors. However, the greatest increases in activity and protein levels were observed in liver metastases. Additionally, six metastatic lesions were obtained in which synchronous primary tumor was resected. In each of these liver metastases, pp60c-src activity and level were significantly increased relative to the corresponding primary tumor, as well as to normal colonic mucosa. Our results demonstrate that progression of colon primary tumors to liver metastases correlates with increased pp60c-src kinase activity and protein level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the SRC activation signature score was significantly associated with metastasis and primary tumor stage I-IV progression (Fig. 2g,h), in agreement with previous studies in CRC [37–40].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Talamonti et al reported increased activity and expression of SFKs in progressive stages of human colorectal cancer, suggesting that colon cancer progression may be dependent on increased SFK protein level and subsequent activity (Talamonti et al., 1993).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Talamonti et al., 1993
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Higher expression and activity of SRC has been documented in primary colon tumors compared with benign polyps or non-transformed colonic mucosa, and increased activity is observed in progressive stages of CRC [23–26].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [25]
In the citing paper
“However, c-Src seems to experience a robust increase in expression and activity in CRC liver metastases compared with metastases derived from other tumors types [11, 12]”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [12]
In the citing paper
“C-src, though, seems to have a robust increase regarding expression and activity in CRC liver metastases compared to those derived from other tumors types.3,11,13”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [11]
In the citing paper
“In CRC cell lines and primary tumors, both c-src kinase activity and protein expression levels have been found elevated compared either to normal colonic mucosal cells and fibroblasts or normal adjacent tissue, respectively.3,10,11”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [11]
In the citing paper
“Increased specific activity and expression levels have been detected in colonic polyps of high malignant potential and severe dysplasia.11,12”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,311
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Identification and characterization of the familial adenomatous polyposis coli gene
Groden, J. L., Thliveris, A. T., Samowitz, W. S., Carlson, M. L., Gelbert, L. M., Albertsen, H., Joslyn, G., Stevens, J., Spirio, L. N., Robertson, M. A., et al. (1991) · Cell · doi:10.1016/0092-8674(81)90021-0 · Cited by 2,794
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler‐Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,701
Identification of FAP Locus Genes from Chromosome 5q21
Kinzler, K. W., Nilbert, M. C., Su, L.-K., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. J., Preisinger, A. C., Hedge, P., McKechnie, D., et al. (1991) · Science · doi:10.1126/science.1651562 · Cited by 2,331
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,097
Mutations of Chromosome 5q21 Genes in FAP and Colorectal Cancer Patients
Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., Hedge, P., et al. (1991) · Science · doi:10.1126/science.1651563 · Cited by 1,891
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., BOOM, J. H. V., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860
Cited by
Sorted by citations
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
Role of Src expression and activation in human cancer
Irby, R., & Yeatman, T. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203912 · Cited by 878
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
Self-citationSrc in cancer: deregulation and consequences for cell behaviour
Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 696
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G. E., Lin, H., Arlinghaus, R. B., & Talpaz, M. (2002) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 677
Self-citationThe interplay between Src and integrins in normal and tumor biology
Playford, M. P., & Schaller, M. D. (2004) · Oncogene · doi:10.1038/sj.onc.1208080 · Cited by 532
Banerjee, M., Cui, X., Li, Z. F., Yu, H. M., Cai, L., Jia, X., He, D., Wang, C., Gao, T., & Xie, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-29995-2 · Cited by 508
Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies
Jiang, H., Zhang, X., Chen, X., Aramsangtienchai, P., Tong, Z., & Lin, H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00750 · Cited by 518
Activating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489
Gray, M. J., Zhang, J., Ellis, L. M., Semenza, G. L., Evans, D. B., Watowich, S. S., & Gallick, G. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208513 · Cited by 378
Self-citationSrc-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling
Avizienyte, E., Wyke, A. W., Jones, R. J., McLean, G. W., Westhoff, M., Brunton, V. G., & Frame, M. C. (2002) · Nature Cell Biology · doi:10.1038/ncb829 · Cited by 376
The Role of Src in Solid Tumors
Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346
Bjorge, J. D., Pang, A., & Fujita, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004852200 · Cited by 321
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 297
Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family Kinases
Osherov, N., & Levitzki, A. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.1047b.x · Cited by 279
Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis
Allgayer, H., Boyd, D. D., Heiss, M. M., Abdalla, E. K., Curley, S. A., & Gallick, G. E. (2002) · Cancer · doi:10.1002/cncr.10221 · Cited by 251
Self-citationOverexpression and Activation of the Tyrosine Kinase Src in Human Pancreatic Carcinoma
Lutz, M. P., Eßer, I. B. S., Flossmann-Kast, B. B. M., Vogelmann, R., Lührs, H., Friess, H., Büchler, M. W., & Adler, G. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.8043 · Cited by 248
Protein myristoylation in health and disease
Wright, M. H., Heal, W. P., Mann, D. J., & Tate, E. W. (2009) · Journal of Chemical Biology · doi:10.1007/s12154-009-0032-8 · Cited by 258
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244
c-Src, Receptor Tyrosine Kinases, and Human Cancer
Biscardi, J. S., Tice, D. A., & Parsons, S. J. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60774-5 · Cited by 243
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., et al. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.01.002 · Cited by 238
Park, S. I., Zhang, J., Phillips, K. A., Araujo, J. C., Najjar, A. M., Volgin, A. Y., Gelovani, J. G., Kim, S., Wang, Z., & Gallick, G. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2997 · Cited by 233
Self-citationUnni, E., Sun, S., Nan, B., McPhaul, M. J., Cheskis, B. J., Mancini, M. A., & Marcelli, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1121 · Cited by 233
Shakibaei, M., Mobasheri, A., Lueders, C., Busch, F., Shayan, P., & Goel, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057218 · Cited by 228
Wallez, Y., Cand, F., Cruzalegui, F. H., Wernstedt, C., Souchelnytskyi, S., Vilgrain, I., & Huber, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209855 · Cited by 238
Treatment for Advanced Tumors: Src Reclaims Center Stage
Summy, J. M., & Gallick, G. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2692 · Cited by 224
Self-citationSrc activation regulates anoikis in human colon tumor cell lines
Windham, T. C., Parikh, N. U., Siwak, D. R., Summy, J. M., McConkey, D. J., Kraker, A. J., & Gallick, G. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205989 · Cited by 219
Self-citationBrunton, V. G., Avizienyte, E., Fincham, V. J., Serrels, B., Metcalf, C. A., Sawyer, T. K., & Frame, M. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1949 · Cited by 217
Trevino, J. G., Summy, J. M., Lesslie, D. P., Parikh, N. U., Hong, D. S., Lee, F. Y., Donato, N. J., Abbruzzese, J. L., Baker, C. H., & Gallick, G. E. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050570 · Cited by 206
Self-citationLu, X., Xie, W., Reed, D. W., Bradshaw, W. S., & Simmons, D. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7961 · Cited by 204
Rosen, K. V., Loza‐Coll, M., Li, A., & Filmus, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106424200 · Cited by 201
Ellis, L. M., Staley, C. A., Liu, W., Fleming, R., Parikh, N. U., Bucana, C. D., & Gallick, G. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.2.1052 · Cited by 200
Self-citationLoss of Tankyrase-Mediated Destruction of 3BP2 Is the Underlying Pathogenic Mechanism of Cherubism
Levaot, N., Voytyuk, O., Dimitriou, I. D., Sircoulomb, F., Chandrakumar, A. A., Deckert, M., Krzyzanowski, P. M., Scotter, A. J., Gu, S. S., Janmohamed, S., et al. (2011) · Cell · doi:10.1016/j.cell.2011.10.045 · Cited by 193
The role of Src in prostate cancer
Fizazi, K. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm086 · Cited by 184
Tavares, S., Vieira, A. F., Taubenberger, A. V., Araújo, M., Martins, N. P., Brás‐Pereira, C., Polónia, A., Herbig, M., Barreto, C., Otto, O., et al. (2017) · Nature Communications · doi:10.1038/ncomms15237 · Cited by 182
Regulation of cell structure and function by actin‐binding proteins: Villin's perspective
Khurana, S., & George, S. P. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.02.040 · Cited by 176
Plé, P. A., Green, T. P., Hennequin, L. F., Curwen, J., Fennell, M., Allen, J. M., der Brempt, C. L., & Costello, G. F. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030317k · Cited by 170
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation
Zhu, S., Bjorge, J. D., & Fujita, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4338 · Cited by 168
Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry
Brunton, V. G., Macpherson, I. R., & Frame, M. C. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.04.010 · Cited by 170
SRC gene expression in human cancer: the role of transcriptional activation
Dehm, S. M., & Bonham, K. (2004) · Biochemistry and Cell Biology · doi:10.1139/o03-077 · Cited by 169
Kopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2246 · Cited by 160
Self-citationCurrent status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Ortiz, M. A., Mikhailova, T., Li, X., Porter, B. A., Bah, A., & Kotula, L. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00750-x · Cited by 163
Biology of colorectal liver metastases: A review
Bird, N. C., MANGNALL, D., & Majeed, A. W. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20558 · Cited by 159
Demetri, G. D., Lo Russo, P., MacPherson, I. R. J., Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agrawal, S., Voi, M., & Evans, T. R. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0224 · Cited by 150
Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells
Nautiyal, J., Kanwar, S. S., Yu, Y., & Majumdar, A. P. N. (2011) · Journal of Molecular Signaling · doi:10.1186/1750-2187-6-7 · Cited by 149
Receptor tyrosine kinases expressed in metastatic colon cancer
Craven, R. J., Xu, L., Weiner, T. M., Fridell, Y.-W. C., Dent, G. A., Srivastava, S., Varnum, B. C., Liu, E. T., & Cance, W. G. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600611 · Cited by 146
Kraker, A. J., Hartl, B. G., Amar, A. M., Barvian, M. R., Showalter, H. D., & Moore, C. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00405-6 · Cited by 140
SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models
Golas, J. M., Lucas, J., Etienne, C., Golas, J., Discafani, C., Sridharan, L., Boghaert, E., Arndt, K., Ye, F., Boschelli, D. H., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2484 · Cited by 134
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“…to malignant transformation in CRC. Talamonti et al reported increased activity and expression of SFKs in progressive stages of human colorectal cancer, suggesting that colon cancer progression may be dependent on increased SFK protein level and subsequent activity (Talamonti et al., 1993).”
BackgroundKlutchko, S. R., Hamby, J. M., Boschelli, D. H., Wu, Z., Kraker, A. J., Amar, A. M., Hartl, B. G., Shen, C., Klohs, W. D., Steinkampf, R. W., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9802259 · Cited by 130
The Role of Src in Colon Cancer and Its Therapeutic Implications
Chen, J., Elfiky, A. A., Han, M., Chen, C., & Saif, M. W. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.10.003 · Cited by 129
Lesslie, D. P., Summy, J. M., Parikh, N. U., Fan, F., Trevino, J., Sawyer, T. K., Metcalf, C. A., Shakespeare, W. C., Hicklin, D. J., Ellis, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603143 · Cited by 126
Self-citationJohnson, F. M., Agrawal, S., Burris, H. A., Rosen, L. S., Dhillon, N., Hong, D. S., Blackwood‐Chirchir, A., Luo, F. R., Sy, O., Kaul, S., et al. (2010) · Cancer · doi:10.1002/cncr.24927 · Cited by 124
Serrels, A., Macpherson, I. R., Evans, T. R. J., Lee, F. Y., Clark, E. A., Sansom, O. J., Ashton, G. H. S., Frame, M. C., & Brunton, V. G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0382 · Cited by 126
Irby, R., & Yeatman, T. J. (2002) · PubMed · Cited by 123
Ubiquitin-dependent degradation of active Src
Hakak, Y., & Martin, G. S. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80453-9 · Cited by 126
Src kinase contributes to the metastatic spread of carcinoma cells
Boyer, B., Bourgeois, Y., & Poupon, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205298 · Cited by 123
BRK/Sik expression in the gastrointestinal tract and in colon tumors.
Llor, X., Serfas, M. S., Bie, W., Vasioukhin, V. I., Polonskaia, M., Derry, J. M. J., Abbott, C. M., & Tyner, A. L. (1999) · PubMed · Cited by 115
Koppikar, P., Choi, S.-H., Egloff, A. M., Cai, Q., Suzuki, S., Freilino, M. L., Nozawa, H., Thomas, S. M., Gooding, W. E., Siegfried, J. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5226 · Cited by 113
Adhesion-linked kinases in cancer; emphasis on Src, focal adhesion kinase and PI 3-kinase
Jones, R. J., Brunton, V., & Frame, M. C. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00153-2 · Cited by 117
Kazansky, A. V., Kabotyanski, E. B., Wyszomierski, S. L., Mancini, M. A., & Rosen, J. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22484 · Cited by 112
Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
Chan, C. M., Jing, X., Pike, L. A., Zhou, Q., Lim, D., Sams, S. B., Lund, G. S., Sharma, V., Haugen, B. R., & Schweppe, R. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3359 · Cited by 113
Coluccia, A. M. L., Benati, D., Dekhil, H., Filippo, A. D., Lan, C., & Gambacorti-Passerini, C. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2057 · Cited by 113
pp60c-src activation in lung adenocarcinoma
Masaki, T., Igarashi, K., Tokuda, M., Yukimasa, S., Han, F., Jin, Y. J., Li, J. Q., Yoneyama, H., Uchida, N., Fujita, J., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00276-4 · Cited by 114
Potential role of N-myristoyltransferase in cancer
Selvakumar, P., Lakshmikuttyamma, A., Shrivastav, A., Das, S. B., Dimmock, J. R., & Sharma, R. K. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.05.002 · Cited by 113
Egan, C., Pang, A., Durda, D., Cheng, H., Wang, J. H.-C., & Fujita, D. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202233 · Cited by 108
Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Warmuth, M., Damoiseaux, R. D., Liu, Y., Fabbro, D., & Gray, N. S. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454126 · Cited by 111
Sun, C. K.-W., Man, K., Ng, T., Ho, J., Lim, Z. X. H., Cheng, Q., Lo, C. M., Poon, R. T. P., & Fan, S. T. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn203 · Cited by 107
Emami, S., Floch, N. L., Bruyneel, E. A., Thim, L., May, F. E. B., Westley, B. R., Rio, M., Mareel, M. M. K., & Gespach, C. P. (2001) · The FASEB Journal · doi:10.1096/fj.00-0355com · Cited by 106
Bandyopadhyay, G. K., Biswas, T., Roy, K. C., Mandal, S., Mandal, C., Pal, B. C., Bhattacharya, S., Rakshit, S., Bhattacharya, D. K., Chaudhuri, U., et al. (2004) · Blood · doi:10.1182/blood-2003-11-4065 · Cited by 106
Saud, S. M., Young, M. R., Jones‐Hall, Y., Ileva, L. V., Evbuomwan, M. O., Wise, J., Colburn, N. H., Kim, Y. S., & Bobe, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0525 · Cited by 102
Dasatinib: An Anti-Tumour Agent via Src Inhibition
Gnoni, A., Marech, I., Silvestris, N., Vacca, A., & Lorusso, V. (2011) · Current Drug Targets · doi:10.2174/138945011794751591 · Cited by 103
Laird, A., Li, G., Moss, K. G., Blake, R. A., Broome, M. A., Cherrington, J. M., & Mendel, D. B. (2003) · PubMed · Cited by 101
EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer
Wang, Y.-W., Cheng, H.-L., Ding, Y.-R., Chou, L.-H., & Chow, N.-H. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.04.004 · Cited by 100
Bauer, T. W., Somcio, R., Fan, F., Liu, W., Johnson, M., Lesslie, D. P., Evans, D. B., Gallick, G. E., & Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0175 · Cited by 99
Self-citationRitchie, S. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg246 · Cited by 97
Yamagata, H., Matsuzaki, K., Mori, S., Yoshida, K., Tahashi, Y., Furukawa, F., Sekimoto, G., Watanabe, T., Uemura, Y., Sakaida, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.157.65.1 · Cited by 97
Barbolina, M. V., Adley, B. P., Ariztia, E. V., Liu, Y., & Stack, M. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608428200 · Cited by 92
Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis
Wei, L., Yu, Y., Zhang, X., & Yu, Q. (2004) · Oncogene · doi:10.1038/sj.onc.1208091 · Cited by 91
Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer
Rajeshkumar, N. V., Tan, A. C., Oliveira, E. D., Womack, C., Wombwell, H., Morgan, S. R., Warren, M. V., Walker, J., Green, T. P., Jimeno, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3021 · Cited by 93
Src-mediated regulation of E-cadherin and EMT in pancreatic cancer
Nagathihalli, N. S. (2012) · Frontiers in bioscience · doi:10.2741/4037 · Cited by 90
Synthesis and Src Kinase Inhibitory Activity of a Series of 4-Phenylamino-3-quinolinecarbonitriles
Boschelli, D. H., Wang, Y. D., Ye, F., Wu, B., Zhang, N., Dutia, M. D., Powell, D. W., Wissner, A., Arndt, K. T., Weber, J. M., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000420z · Cited by 90
Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications
Jin, W. (2020) · Cancers · doi:10.3390/cancers12051339 · Cited by 86
The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy
Lieu, C. H., & Kopetz, S. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.012 · Cited by 87
Chellappa, K., Jankova, L., Schnabl, J. M., Pan, S., Brélivet, Y., Fung, C. L.-S., Chan, C., Dent, O. F., Clarke, S. J., Robertson, G. R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106799109 · Cited by 87
Identification of Src transformation fingerprint in human colon cancer
Malek, R. L., Irby, R. B., Guo, Q. M., Lee, K., Wong, S., He, M., Tsai, J., Frank, B., Liu, E. T., Quackenbush, J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205900 · Cited by 81
The sensors and regulators of cell–matrix surveillance in anoikis resistance of tumors
Nagaprashantha, L. D., Vatsyayan, R., Lelsani, P. C. R., Awasthi, S., & Singhal, S. S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25725 · Cited by 84
Jones, R. J., Avizienyte, E., Wyke, A. W., Owens, D. W., Brunton, V. G., & Frame, M. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600594 · Cited by 80
Summy, J. M., Trevino, J. G., Lesslie, D. P., Baker, C. H., Shakespeare, W. C., Wang, Y., Sundaramoorthi, R., Metcalf, C. A., Keats, J. A., Sawyer, T. K., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0171 · Cited by 82
Self-citationLee, Y.-C., Huang, C.-F., Murshed, M., Chu, K., Araujo, J. C., Ye, X., deCrombrugghe, B., Yu-Lee, L.-Y., Gallick, G. E., & Lin, S.-H. (2010) · Oncogene · doi:10.1038/onc.2010.73 · Cited by 79
Self-citationBosutinib: A review of preclinical studies in chronic myelogenous leukaemia
Boschelli, F., Arndt, K. T., & Gambacorti-Passerini, C. B. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.032 · Cited by 80
c‐Src drives intestinal regeneration and transformation
Cordero, J. B., Ridgway, R. A., Valeri, N., Nixon, C., Frame, M. C., Muller, W. J., Vidal, M., & Sansom, O. J. (2014) · The EMBO Journal · doi:10.1002/embj.201387454 · Cited by 77
Tao, J., Zhi, X., Zhang, X., Fu, M., Huang, H., Fan, Y. J., Guan, W., & Zou, C. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0253-3 · Cited by 77
Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway
Rieger‐Christ, K., Lee, P., Zagha, R. M., Kosakowski, M., Moinzadeh, A., Stoffel, J. T., Ben‐Ze'ev, A., Libertino, J. A., & Summerhayes, I. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207629 · Cited by 76
Molecular mechanisms of hepatic metastasis in colorectal cancer
Rudmik, L. R., & Magliocco, A. M. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20393 · Cited by 76
Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma
Azuma, K., Tanaka, M., Uekita, T., Inoue, S., Yokota, J., Ouchi, Y., & Sakai, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208654 · Cited by 75
Maa, M., Lee, J., Chen, Y.-J., Chen, Y., Lee, Y.-C., Wang, S., Huang, C.-C., Chow, N.-H., & Leu, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610280200 · Cited by 76
Liu, W., Yue, F., Zheng, M., Merlot, A. M., Bae, D.-H., Huang, M., Lane, D. J. R., Jansson, P. J., Liu, G., Richardson, V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3316 · Cited by 76
Leslie, A., Pratt, N. R., Gillespie, K., Sales, M., Kernohan, N. M., Smith, G. C., Wolf, C. R., Carey, F. A., & Steele, R. J. (2003) · PubMed · Cited by 75
Metadata
- Authors
- Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Talamonti, M S
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 53-60
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC329994
- OpenAlex
- W2030565228
- Cited by
- 399
- References
- 45
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 11 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 6 · 2018: 6 · 2017: 14 · 2016: 8 · 2015: 13 · 2014: 11 · 2013: 17 · 2012: 24
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca053167-06)
- National Cancer Institute (CA09599, CA53167, T32CA009599)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src kinase, tyrosine kinase activity, colorectal cancer, tumor progression, colonic polyps, liver metastasis, synchronous primary tumors, oncogene activation
- MeSH terms
- Adenocarcinoma, Adenoma, Antigen-Antibody Complex, Colonic Neoplasms, Colonic Polyps, Humans, Intestinal Mucosa, Liver Neoplasms, Neoplasm Metastasis, Neoplasm Staging, Phosphopyruvate Hydratase, Phosphorylation, Protein Kinases, Protein-Tyrosine Kinases, Rectal Neoplasms, Reference Values, Immunoblotting, Proto-Oncogene Proteins pp60(c-src)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
